Vermeire S, Schreiber S, Rubin DT, D'Haens G, et al. Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol 2024 Dec 2:S2468-1253(24)00272.
PMID: 39637881